(Q38848311)

7 September 2017

title

A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries (English)

1 reference

7 September 2017

0 references

anti-retroviral agent

0 references

Lut Lynen

8

0 references

Harriet Mayanja-Kizza

object named as

Harriet Mayanja-Kizza

13

0 references

Sabrina Bakeera-Kitaka

7

object named as

Sabrina Bakeera-Kitaka

1 reference

7 September 2017

1

Robert Colebunders

1 reference

7 September 2017

11

Thomas C Quinn

1 reference

7 September 2017

10

Steven J Reynolds

1 reference

7 September 2017

9

Lisa Spacek

1 reference

7 September 2017

Kamya R Moses

2

1 reference

7 September 2017

John Laurence

3

1 reference

7 September 2017

Hasan M Shihab

4

1 reference

7 September 2017

Fred Semitala

5

1 reference

7 September 2017

Fred Lutwama

6

1 reference

7 September 2017

Brant Viner

12

1 reference

7 September 2017

publication date

1 January 2006

1 reference

Lancet Infectious Diseases

7 September 2017

published in

1 reference

7 September 2017

volume

6

1 reference

7 September 2017

issue

1

1 reference

7 September 2017

page(s)

53-59

1 reference

Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Monitoring HIV treatment in the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1???Positive Individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Comparison of an assay using signal amplification of the heat-dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Pediatric human immunodeficiency virus screening in an African district hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Monitoring treatment: at what cost?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

CD4 and total lymphocyte counts as predictors of HIV disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Changes in Total Lymphocyte Count as a Surrogate for Changes in CD4 Count Following Initiation of HAART: Implications for Monitoring in Resource-Limited Settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Use of total lymphocyte count for monitoring response to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Highly active antiretroviral therapy associated with improved anemia among HIV-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

New nucleoside/nucleotide backbone options: a review of recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Pharmacokinetic Drug Interactions with Nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Measurement of Adherence to Antiretroviral Medications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Virologic correlates of adherence to antiretroviral medications and therapeutic failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970327-3

7 January 2021

10.1016/S1473-3099(05)70327-3

Identifiers

DOI

1 reference

7 September 2017

1 reference